Genentech: PharmaVitae Profile

Genentech: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Genentech in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

CHAPTER 1 EXECUTIVE SUMMARY 2
Key findings 2
Historical and forecast ethical sales performance 3
Therapeutic strategy 5
Launch and expiry outlook 9
Externalization, geographic and molecule type strategies 12
Externalization strategy 13
Geographic strategy 14
Molecule type strategy 14
SWOT analysis 16
Strengths 16
Weaknesses 18
Opportunities 20
Threats 22
CHAPTER 2 CORPORATE HISTORY 26
Key findings 26
Background 27
Key corporate developments 28
Founding 28
Genentech's first product 28
Genentech's first mAb therapy 29
Genentech timeline 31
M&A history 32
Genentech's history with its partner Roche 32
Genentech's agreement with Roche 33
Genentech's closest biotech peer seems to be following a growth by acquisition strategy 34
...but Genentech set to acquire Tanox 35
A low-risk acquisition with obvious synergies and long-term potential 36
FTC request connotes a potential acquisition delay 37
Current corporate structure 38
Current management team 39
CHAPTER 3 HISTORICAL PERFORMANCE 40
Key findings 40
Introduction 41
Revenue and growth rate analysis, 2001-06 41
Revenue and growth rate vs. peer set 43
Product analysis, 2001-06 47
Growth drivers 48
Avastin 48
Rituxan 48
Herceptin 49
Xolair 49
Tarceva 50
Lucentis 50
Growth resistors 50
Operating revenue and cost analysis, 2001-06 51
Operating revenue/cost analysis 53
CHAPTER 4 FORECAST PERFORMANCE 55
Key findings 55
Introduction 56
Revenue and growth rate, 2006-12 56
Product analysis, 2006-12 58
Growth drivers 63
Avastin 63
Herceptin 64
Rituxan 64
Lucentis 65
Tarceva 65
Growth resistors 66
Raptiva 66
Protropin/Nutropin 66
Therapy area analysis, 2006-12 69
Oncology 72
'Other' 73
Immunology & inflammation 73
Other therapy areas 74
Therapy area focus 74
Launches and expiries analysis, 2006-12 79
Launch portfolio 79
Core portfolio 81
Expiry portfolio 83
Launch/core/expiry configuration 85
Externalization analysis, 2006-12 89
Geographic analysis, 2006-12 95
Molecule type analysis, 2006-12 99
CHAPTER 5 KEY PRODUCTS AND COMPETITORS 106
Key findings 106
Overview 107
Oncology 108
Avastin 108
Overview 108
Sales forecast 109
Newsflow 109
Competitive landscape 111
Rituxan 115
Overview 115
Sales forecast 116
Newsflow 116
Competitive landscape 117
Herceptin 119
Overview 119
Sales forecast 120
Newsflow 121
Competitive landscape 122
Tarceva 124
Overview 124
Sales forecast 125
Newsflow 125
Competitive landscape 126
Pertuzumab 129
Pertuzumab 129
Overview 129
Sales forecast 130
Newsflow 130
Competitive landscape 131
Immunology & inflammation 133
Rituxan RA 133
Overview 133
Sales forecast 134
Newsflow 134
Competitive landscape 135
Ocrelizumab 138
Overview 138
Sales forecast 139
Newsflow 140
Competitive landscape 140
CNS 142
Rituxan MS 142
Overview 142
Sales forecast 143
Newsflow 144
Competitive landscape 145
Other 147
Lucentis (ranibizumab) 147
Overview 147
Sales forecast 148
Newsflow 149
Competitive landscape 149
R&D pipeline analysis 152
CHAPTER 6 APPENDIX 160
IMS vs. company-reported data reconciliation 160
References 163
References 163
Datamonitor reports 163
Abbreviations 163
List of Tables
Table 1: Tanox's pipeline offering 36
Table 2: Genentech Corporate Executive Committee 39
Table 3: Peer set overview 43
Table 4: Operating revenue/cost analysis ($m), 2001-06 51
Table 5: Operating cost ratio analysis (% of total revenues), 2001-06 53
Table 6: Product portfolio overview, sales ($m), 2006-12 58
Table 7: Therapy area overview, sales ($m), 2006-12 69
Table 8: Launch portfolio overview, sales ($m), 2006-12 80
Table 9: Core portfolio overview, sales ($m), 2006-12 82
Table 10: Expiry portfolio overview, sales ($m), 2006-12 84
Table 11: Externally developed portfolio ($m), 2006-12 90
Table 12: Molecule type overview, sales ($m), 2006-12 99
Table 13: Key products overview 107
Table 14: Avastin: overview 108
Table 15: Avastin: sales forecast ($m), 2006-12 109
Table 16: Avastin: newsflow 109
Table 17: Rituxan: overview 115
Table 18: Rituxan: sales forecast ($m), 2006-12 116
Table 19: Rituxan: newsflow 116
Table 20: Herceptin: overview 119
Table 21: Herceptin: sales forecast ($m), 2006-12 120
Table 22: Herceptin: newsflow 121
Table 23: Tarceva: overview 124
Table 24: Tarceva: sales forecast ($m), 2006-12 125
Table 25: Tarceva: newsflow 125
Table 26: Pertuzumab: overview 129
Table 27: Pertuzumab: sales forecast ($m), 2006-12 130
Table 28: Pertuzumab: newsflow 130
Table 29: Rituxan RA: overview 133
Table 30: Rituxan RA: sales forecast ($m), 2006-12 134
Table 31: Rituxan RA: newsflow 134
Table 32: Ocrelizumab: overview 138
Table 33: Ocrelizumab: sales forecast ($m), 2006-12 139
Table 34: Ocrelizumab: newsflow 140
Table 35: Rituxan MS: overview 142
Table 36: Rituxan MS: sales forecast ($m), 2006-12 143
Table 37: Rituxan MS: newsflow 144
Table 38: Lucentis: overview 147
Table 39: Lucentis: sales forecast ($m), 2006-12 148
Table 40: Lucentis: newsflow 149
Table 41: Genentech's R&D pipeline (Phase I-registration) 152
Table 42: Genentech's indication broadening pipeline (Phase I-registration) 157
List of Figures
Figure 1: Historical and forecast ethical sales performance (% CAGR), Genentech and biotechnology peer set 3
Figure 2: Therapeutic focus vs. biotechnology peer set (%), 2006 6
Figure 3: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Genentech 9
Figure 4: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set 11
Figure 5: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2006 12
Figure 6: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2012 13
Figure 7: SWOT analysis of Genentech 16
Figure 8: Genentech timeline 31
Figure 9: Corporate structure 38
Figure 10: Revenue & growth rate (ethical sales) ($m), 2001-06 41
Figure 11: Ethical revenue ($m) and growth rate (%) vs. peer set, 2001-06 45
Figure 12: Growth drivers/resistor products of historical revenue performance ($m), 2001-06 47
Figure 13: Operating revenue/cost analysis ($m), 2001-06 52
Figure 14: Operating cost ratio analysis (% of total revenues), 2001-06 54
Figure 15: Ethical revenue ($m) and growth rate (%), 2006-12 56
Figure 16: Top five products by sales ($m), 2006 61
Figure 17: Top five products by sales ($m), 2012 62
Figure 18: Growth drivers and resistors by product, 2006-12 63
Figure 19: Key strategic products, sales ($m), 2006-12 67
Figure 20: Ethical sales by therapy area ($m), 2006-12 71
Figure 21: Growth drivers and resistors by therapy area (%), 2006-12 72
Figure 22: Ethical sales by therapy area (%), 2006-12 75
Figure 23: Therapy area focus compared with peer set (% total ethical sales), 2006 77
Figure 24: Therapy area focus compared with peer set (% total ethical sales), 2012 78
Figure 25: Launch schedule, sales ($m), 2006-12 81
Figure 26: Core products sales growth ($m), 2006-12 83
Figure 27: Expiry schedule, sales ($m), 2006-12 85
Figure 28: Launch, core and expiry, sales ($m), 2006-12 86
Figure 29: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Genentech 87
Figure 30: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set 88
Figure 31: Externalization dependency, sales ($m), 2006-12 91
Figure 32: Growth drivers and resistors, externally vs. internally discovered products, sales ($m), 2006-12 92
Figure 33: Externalization dependency vs. peer set, % total sales, 2006 93
Figure 34: Externalization dependency vs. peer set, % total sales, 2012 94
Figure 35: Geographical sales breakdown ($m), 2006-12 95
Figure 36: Growth drivers and resistors by geography, sales ($m), 2006-12 96
Figure 37: US dependency vs. peer set, % total sales, 2006 97
Figure 38: US dependency vs. peer set, % total sales, 2012 98
Figure 39: Molecule type sales breakdown ($m), 2006-12 100
Figure 40: Growth drivers and resistors by molecule type, sales ($m), 2006-12 101
Figure 41: Biologics dependency vs. peer set, % total sales, 2006 104
Figure 42: Biologics dependency vs. peer set, % total sales, 2012 105
Figure 43: Genentech's Phase I-III pipeline split by therapy area 154
Figure 44: Genentech's Phase I-III pipeline split by molecule type 155
Figure 45: Genentech's Phase I-III pipeline split by externalization 156
Figure 46: IMS vs. company-reported ethical sales discrepancy ($m), 2006 161
Figure 47: IMS vs. company-reported ethical sales forecast growth rates (%), 2006-12 162